TradingKey

关于 Edwards Lifesciences Corp 公司

Edwards Lifesciences Corporation 是一家全球性结构性心脏创新公司。该公司致力于以患者为中心的结构性心脏病医疗创新，并投资于研发，以改变结构性心脏病患者的护理。其产品分为几类，包括经导管主动脉瓣置换术 (TAVR)、经导管二尖瓣和三尖瓣治疗 (TMTT) 和外科结构性心脏 (外科)。该公司开发了经导管心脏瓣膜置换技术，旨在以微创方式置换主动脉瓣膜。Edwards SAPIEN 系列瓣膜包括 Edwards SAPIEN 3、Edwards SAPIEN 3 Ultra 和 Edwards SAPIEN 3 Ultra RESILIA 系统，这些系统是基于导管的治疗方法，用于治疗严重的症状性主动脉瓣狭窄。其 PASCAL PRECISION 和 Cardioband 经导管瓣膜修复系统已在欧洲上市，用于二尖瓣和三尖瓣修复。

公司简介

公司代码EW

公司名称Edwards Lifesciences Corp

上市日期Mar 27, 2000

成立日期1999

CEOMr. Bernard J. Zovighian

员工数量15800

证券类型Ordinary Share

年结日Mar 27

公司地址One Edwards Way

城市IRVINE

上市交易所NYSE Consolidated

国家United States of America

邮编92614

电话19492502500

网址https://www.edwards.com

公司代码EW

上市日期Mar 27, 2000

成立日期1999

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

业务USD

名称

营收

占比

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

地区USD

名称

营收

占比

United States

838.90M

59.38%

Europe

341.80M

24.19%

Rest of the world

150.20M

10.63%

Japan

81.80M

5.79%

业务

地区

业务USD

名称

营收

占比

Transcatheter Aortic Valve Replacement

1.05B

74.09%

Surgical Heart Valve Therapy

250.90M

17.76%

Transcatheter Mitral and Tricuspid Therapies

115.20M

8.15%

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

持股股东

占比

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

股东类型

持股股东

占比

Investment Advisor

43.28%

Investment Advisor/Hedge Fund

31.39%

Hedge Fund

5.44%

Research Firm

2.22%

Pension Fund

2.19%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.53%

Individual Investor

0.92%

Endowment Fund

0.82%

Other

10.30%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

2586

529.26M

90.23%

-21.68M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

68.94M

11.75%

+70.46K

+0.10%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

32.28M

5.5%

+544.18K

+1.71%

Mar 31, 2025

Wellington Management Company, LLP

29.13M

4.97%

-4.08M

-12.27%

Mar 31, 2025

State Street Global Advisors (US)

25.78M

4.4%

-25.16K

-0.10%

Mar 31, 2025

JP Morgan Asset Management

16.37M

2.79%

+5.61M

+52.12%

Mar 31, 2025

Citadel Advisors LLC

13.38M

2.28%

+3.96M

+42.09%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.68M

2.16%

-970.48K

-7.11%

Mar 31, 2025

Jennison Associates LLC

10.09M

1.72%

+2.58M

+34.31%

Mar 31, 2025

Fisher Investments

10.10M

1.72%

+325.19K

+3.33%

Mar 31, 2025

Walter Scott & Partners Ltd.

9.06M

1.54%

-347.38K

-3.69%

Mar 31, 2025

持股ETF

更新时间: 10 小时前

机构名称

占比

iShares U.S. Medical Devices ETF

4.56%

Future Fund Long/Short ETF

3.72%

iShares Health Innovation Active ETF

3.18%

Adaptive Core ETF

3.15%

Global X Aging Population ETF

3.13%

Tema Heart & Health ETF

2.28%

First Trust Indxx Medical Devices ETF

2.08%

SPDR S&P Health Care Equipment ETF

1.89%

Invesco S&P 500 Equal Weight Health Care ETF

1.72%

PGIM Jennison Better Future ETF

1.71%

iShares U.S. Medical Devices ETF

占比4.56%

Future Fund Long/Short ETF

占比3.72%

iShares Health Innovation Active ETF

占比3.18%

Adaptive Core ETF

占比3.15%

Global X Aging Population ETF

占比3.13%

Tema Heart & Health ETF

占比2.28%

First Trust Indxx Medical Devices ETF

占比2.08%

SPDR S&P Health Care Equipment ETF

占比1.89%

Invesco S&P 500 Equal Weight Health Care ETF

占比1.72%

PGIM Jennison Better Future ETF

占比1.71%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

May 07, 2020

Split

1>3

公告日期

类型

比率

May 07, 2020

Split

1>3

Edwards Lifesciences Corp

79.330USD

Edwards Lifesciences Corp

79.330

概览

公司

财务